JP2024521566A5 - - Google Patents
Info
- Publication number
- JP2024521566A5 JP2024521566A5 JP2023571468A JP2023571468A JP2024521566A5 JP 2024521566 A5 JP2024521566 A5 JP 2024521566A5 JP 2023571468 A JP2023571468 A JP 2023571468A JP 2023571468 A JP2023571468 A JP 2023571468A JP 2024521566 A5 JP2024521566 A5 JP 2024521566A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- modified
- receptor
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/094830 | 2021-05-20 | ||
| CN2021094830 | 2021-05-20 | ||
| PCT/CN2022/093747 WO2022242700A1 (en) | 2021-05-20 | 2022-05-19 | Genetically modified nk cells and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521566A JP2024521566A (ja) | 2024-06-03 |
| JP2024521566A5 true JP2024521566A5 (enExample) | 2025-05-27 |
Family
ID=84140259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571468A Pending JP2024521566A (ja) | 2021-05-20 | 2022-05-19 | 遺伝子的に改変されたｎｋ細胞およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240285685A1 (enExample) |
| EP (1) | EP4341383A4 (enExample) |
| JP (1) | JP2024521566A (enExample) |
| KR (1) | KR20240010717A (enExample) |
| CN (1) | CN117355600A (enExample) |
| WO (1) | WO2022242700A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202342736A (zh) * | 2022-02-07 | 2023-11-01 | 中國大陸商杭州啟函生物科技有限公司 | 增強免疫療法的系統和方法 |
| EP4353741A1 (en) * | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| CN115820645B (zh) * | 2022-11-28 | 2023-09-22 | 上海恩凯细胞技术有限公司 | 制备沉默nkg2a基因的nk细胞的方法及其用途 |
| CN115948341B (zh) * | 2022-11-28 | 2025-05-16 | 上海恩凯细胞技术有限公司 | 敲低nkg2a基因的car-免疫细胞及其用途 |
| TW202503051A (zh) * | 2023-03-07 | 2025-01-16 | 美商英特利亞醫療公司 | 用於免疫療法之ｃｉｓｈ組合物及方法 |
| CN116590237B (zh) * | 2023-05-29 | 2023-10-31 | 上海贝斯昂科生物科技有限公司 | 一种遗传修饰的自然杀伤细胞及其制备和用途 |
| US12681020B2 (en) | 2024-03-20 | 2026-07-14 | Immunitybio, Inc. | Compositions and methods for NK-92 cells expressing native CD16 |
| CN120989166B (zh) * | 2025-10-21 | 2026-01-23 | 成都蓉生药业有限责任公司 | 一种慢病毒包膜质粒组合及其应用、慢病毒及其包装方法与转导造血干细胞的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL265953B2 (en) * | 2016-10-19 | 2026-05-01 | Cellectis Sa | Gene insertion designed to target for enhanced immune cell therapy |
| WO2018126074A1 (en) * | 2016-12-30 | 2018-07-05 | Celularity, Inc. | Genetically modified natural killer cells |
| CA3093919A1 (en) * | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| SG11202010763VA (en) * | 2018-05-03 | 2020-11-27 | Univ Texas | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
| AU2019386140B2 (en) * | 2018-11-28 | 2026-05-28 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
| BR112021016046A2 (pt) * | 2019-02-15 | 2021-11-09 | Editas Medicine Inc | Células assassinas naturais modificadas (nk) para imunoterapia |
| CN114174325A (zh) * | 2019-06-04 | 2022-03-11 | 恩卡尔塔公司 | 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 |
| EP3789485A1 (en) * | 2019-09-06 | 2021-03-10 | ONK Therapeutics Limited | Cellular therapies for cancer |
-
2022
- 2022-05-19 WO PCT/CN2022/093747 patent/WO2022242700A1/en not_active Ceased
- 2022-05-19 EP EP22804020.0A patent/EP4341383A4/en active Pending
- 2022-05-19 KR KR1020237043004A patent/KR20240010717A/ko active Pending
- 2022-05-19 CN CN202280036465.5A patent/CN117355600A/zh active Pending
- 2022-05-19 US US18/562,547 patent/US20240285685A1/en active Pending
- 2022-05-19 JP JP2023571468A patent/JP2024521566A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20251135T1 (hr) | Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore | |
| CN109503715B (zh) | Il-4r的融合蛋白及其应用 | |
| IL295604A (en) | Methods of making chimeric antigen receptor-expressing cells | |
| US20210269537A1 (en) | Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof | |
| CN112771167B (zh) | 表达有趋化因子的细胞及用途 | |
| KR20200120939A (ko) | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 | |
| EP3822345B1 (en) | Genetically engineered cell and application thereof | |
| JP2022550899A5 (enExample) | ||
| JP2022507830A5 (enExample) | ||
| JP2017513818A5 (enExample) | ||
| CN117683139A (zh) | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 | |
| CN117165532A (zh) | 具有增强的迁移能力的修饰的细胞 | |
| JP2022513164A (ja) | 胎盤由来同種ｃａｒ－ｔ細胞およびその使用 | |
| JP2023516347A (ja) | ＃δＴ細胞及びその使用 | |
| WO2025140265A1 (en) | Combination of chimeric antigen receptor and dap10 in cell therapy | |
| KR20240153592A (ko) | 동종이계 치료용 세포 | |
| WO2024192622A1 (zh) | 用于同种异体移植的工程化细胞 | |
| US20250092363A1 (en) | Placenta-derived allogeneic car-t cells and uses thereof | |
| RU2021108422A (ru) | Способы получения клеток, экспрессирующих химерный антигенный рецептор | |
| HK40115321A (en) | Allogeneic therapeutic cells | |
| JP2026514801A (ja) | 免疫拒絶のリスクが低減された同種異系治療用細胞 | |
| KR20250013199A (ko) | 세포 요법 작제물의 비-바이러스 전달 | |
| CN118126191A (zh) | 靶向TGF-β的嵌合抗原受体及其用途 | |
| EA050762B1 (ru) | Аллогенные терапевтические клетки | |
| KR20250166108A (ko) | 기능이 향상된 세포 치료법 |